title: [Curative effect on aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis, a study of 203 cases].
abstract: OBJECTIVE
  To analyze the curative effect of aggressive B cell non-Hodgkin's lymphoma and relevant influencing factors of its prognosis.
  
  
  METHODS
  The curative effects of aggressive non-Hodgkin's lymphoma which were diagnosed as diffuse small cleaved (E), diffuse mixed (F), diffuse large cell (G) or diffuse immunoblastic lymphoma (H) pathologically and certified as B cell lymphoma immunohistologically and treated with CHOP or other ADM-containing regimens for at least 4 cycles from 1993 to 1997 were analyzed. An analysis of the correlation of prognosis with different factors was made.
  
  
  RESULTS
  The curative effects of 191 out of the 230 cases were evaluated. 131 (68.9%) patients achieved CR, and 47 (24.6%) achieved PR. The 6-year overall survival (OS) rates and progress free survival (PFS) rates were 51.4% and 43.3% respectively. According to IPI risk stratification, the 6-year OS rates were 66.6%, 42.2%, 23.6%, and 10.0% in the low-risk, low-intermediate-risk, high-intermediate-risk, and high risk groups respectively (P = 0.000 0). The 6-year PFS rates were 59.7%, 30.2%, 16.7%, and 10.3% in the low-risk, low intermediate risk, high-intermediate-risk, and high risk groups respectively. The prognosis analysis showed that OS and PFS were significantly correlated with different clinical characteristics such as stage, PS, number of extra-nodal lesions, LDH bulky disease, and B symptom.
  
  
  CONCLUSIONS
  The treatment with CHOP as its main component has a beneficial effect on aggressive B cell lymphoma in low risk group, but is less effective for the low-intermediate, high-intermediate, and high risk.
authors.affiliation: Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
authors.forename: Rui-hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Wen-qi
authors.initials: WQ
authors.lastname: Jiang
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Li
authors.forename: Tong-yu
authors.initials: TY
authors.lastname: Lin
authors.forename: Hui-qiang
authors.initials: HQ
authors.lastname: Huang
authors.forename: Zhong-jun
authors.initials: ZJ
authors.lastname: Xia
authors.forename: Xiao-fei
authors.initials: XF
authors.lastname: Sun
authors.forename: You-jian
authors.initials: YJ
authors.lastname: He
authors.forename: Zhong-zhen
authors.initials: ZZ
authors.lastname: Guan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone